Keiichiro Matsumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Keiichiro Matsumoto has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Akiko Kanaya
Department of Nephrology, Sasebo Kyosai Hospital, Sasebo, Nagasaki, Japan
1 shared publicationKenichi Fukunari
Department of Nephrology, Sasebo Kyosai Hospital, Sasebo, Nagasaki, Japan
1 shared publicationMai Yoshizaki
Department of Nephrology, Sasebo Kyosai Hospital, Sasebo, Nagasaki, Japan
1 shared publicationMakoto Fukuda
Department of Internal Medicine, Saga University Faculty of Medicine, Saga City, Saga, Japan
1 shared publication- Makoto Fukuda
Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan
1 shared publication - Masatora Yamasaki
Department of Internal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga, Japan
1 shared publication
Latest Publications
- Open Access
- 6 July 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 221
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with refractory nephrotic syndrome. A 61-year-old woman was diagnosed with minimal change-type nephrotic syndrome in October 2012. She received prednisolone (PSL) and cyclosporin A (CyA), but she experienced several cycles of relapse and remission and was hospitalized in May 2016 due to relapse. However, in spite of steroid pulse therapy and adrenocorticotropic hormone (ACTH) administration, her urinary protein level did not improve. We started her on evolocumab with the expectation of equivalent LDL-lowering effects as seen with LDL apheresis. After that, the LDL cholesterol level and UP/UC were concomitantly decreased, and the serum albumin was increased. This was maintained even when we reduced the PSL dose. This suggests that evolocumab clinically improves the nephrotic condition. No other report has described the use of evolocumab for nephrotic syndrome (NS) or its effect on similar nephrotic conditions. We believe that the findings presented here are unique and may be beneficial when treating similar cases.
- 6 July 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 221
Open AccessSuccessful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with refractory nephrotic syndrome. A 61-year-old woman was diagnosed with minimal change-type nephrotic syndrome in October 2012. She received prednisolone (PSL) and cyclosporin A (CyA), but she experienced several cycles of relapse and remission and was hospitalized in May 2016 due to relapse. However, in spite of steroid pulse therapy and adrenocorticotropic hormone (ACTH) administration, her urinary protein level did not improve. We started her on evolocumab with the expectation of equivalent LDL-lowering effects as seen with LDL apheresis. After that, the LDL cholesterol level and UP/UC were concomitantly decreased, and the serum albumin was increased. This was maintained even when we reduced the PSL dose. This suggests that evolocumab clinically improves the nephrotic condition. No other report has described the use of evolocumab for nephrotic syndrome (NS) or its effect on similar nephrotic conditions. We believe that the findings presented here are unique and may be beneficial when treating similar cases.
- Open Access
- 1 January 2015
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 16, 119-123
A Report of an Adult Case of Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome, with a Review of 102 Japanese Cases
Background:Although TINU syndrome is characterized by idiopathic TIN with bilateral anterior uveitis, few reports have provided a comprehensive summary of the features of this disorder. Previous reports have suggested that many Japanese patients had ...
- 1 January 2015
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 16, 119-123
Open AccessA Report of an Adult Case of Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome, with a Review of 102 Japanese Cases
Background:Although TINU syndrome is characterized by idiopathic TIN with bilateral anterior uveitis, few reports have provided a comprehensive summary of the features of this disorder. Previous reports have suggested that many Japanese patients had ...